pharmaphorum

AZ’s Forxiga gets heart claim data on its EU label

AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 diabetes therapy Forxiga in the EU which could help it challenge rival drugs in the SGLT2 ...
pharmaphorum

Boehringer, Lilly’s Jardiance tries to match AZ’s Farxiga with heart failure label

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. The US ...

Liquidia Corporation (LQDA) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies Transcript

Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 ...
BMJ

Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial

Introduction Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial ...